Amifampridine (Firdapse)
What studies of Amifampridine (Firdapse) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for fatigue.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Amifampridine (Firdapse) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Amifampridine (Firdapse) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Fatigue1 study · 5 (few people) people took Amifampridine (Firdapse) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (5 in all).
Studies with no comparison group5 in the study · not uniformly reported · individualized: 5 mg; 20 mg per day; initially 2 x 5 mg per day, as needed; long-term medication (few people)
Fatigue improved.
The evidence is very uncertain about the effect of amifampridine (Firdapse) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (5 in all)
See the 1 study
-
- People in the study
- 5 in the study
- Dose
- individualized: 5 mg; 20 mg per day; initially 2 x 5 mg per day, as needed; long-term medication
- Outcome
- Bell score
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
5 mg at the start
- 2Top dose
Most often 5 mg (1 of 1 studies)
Doses across 1 study
5 to 5 mg.
Each study’s dose, as printed
- individualized: 5 mg; 20 mg per day; initially 2 x 5 mg per day, as needed; long-term medication Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials. (2024)
All papers
- Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials.2024 · compared with another group · 5 in the study
Summary
This collective casuistry reports five patients with post-COVID syndrome and fatigue, including one author’s self-observation and relatives, treated off-label with amifampridine at their request. Doses were individualized: 5 mg, long-term medication with 20 mg per day, and initially 2 x 5 mg per day. In two patients, a double-blind discontinuation trial used 3 days verum and 3 days placebo; it was carried out over six days in June 2023. The Bell score and need for sleep per 24 hours were documented daily. The Bell score increased in all five patients, from a mean of 28 ± 16 to 82 ± 20 (p=0.00265, paired t-test). Sleep times fell, for example from 16-18 hours/24 hours to 8-9 hours/24 hours in patient 1, from 12 hours per 24 hours to 7 hours/24h in patient 2, and from 11-12 hours / 24 h to 7-9 hours in patient 3. During placebo discontinuation, patient 2’s Bell score fell from 90 to 60 (day 4) to 20 (day 6), and sleep time increased from 7.5 to 10.0 to 11.0 hours; patient 3’s Bell score fell to 50-60 from day 1, and sleep time increased to up to 11.5 hours (day 2). After verum re-exposure in patient 3, the Bell score normalized to 80 and sleep time decreased to 8.0 hours (day 5). Recurrent fatigue after discontinuation trials occurred after a few days. Side effects for amifampridine were not reported for this study. The authors state that absolute proof requires a randomized double-blind study, which is planned.